EC Number   |
Inhibitors |
Structure |
|---|
   3.4.22.41 | E-64 |
- |
   |
| 3.4.22.41 | EDTA |
6.52% inhibition at 0.1 mM |
|
| 3.4.22.41 | EGTA |
4.72% inhibition at 0.1 mM |
|
| 3.4.22.41 | Hg2+ |
0.81% residual activity at 5 mM |
|
| 3.4.22.41 | JPM565 |
radioactive-labeling by 125I, irrevrsible inhibitor of papin-type cathepsins, active site labeling |
|
| 3.4.22.41 | leupeptin |
complete inhibition at 0.1 mM |
|
| 3.4.22.41 | more |
downregulation of cathepsin F mRNA by E-64d; treatment with retinol/palmitic acid increases mRNA-level of cystatin B coupled with decrease in cathepsin F activity; treatment with retinol/palmitic acid increases mRNA-level of cystatin C coupled with decrease in cathepsin F activity |
|
| 3.4.22.41 | more |
not inhibited by pepstatin A |
|
| 3.4.22.41 | more |
the prodomain effectively inhibits the enzyme in which the ERFNAQ motif plays a critical role in the inhibition, but the GTFD motif is also required for complete inhibition |
|
| 3.4.22.41 | morpholine urea-Leu-homophenylalaninevinyl sulfone-phenyl |
potent and irreversible inhibitor of cysteine proteases |
|
